Quince Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Quince Therapeutics is a biotechnology company focused on developing therapies for rare diseases by leveraging a patient’s own biology. Its lead program, EryDex, delivers a drug by encapsulating dexamethasone sodium phosphate within the patient’s own red blood cells, aiming to improve tolerability, tissue distribution, and pharmacokinetic properties for chronic treatment. The underlying Autologous Intracellular Drug Encapsulation platform is designed to enable the repeated administration of therapies that are limited by toxicity, distribution, pharmacokinetics, or immune responses. The company is based in South San Francisco, California, operating in the biotechnology research sector.

EryDex targets Ataxia-Telangiectasia, a rare pediatric neurodegenerative disease, and Quince is conducting an international Phase 3 NEAT study under a FDA Special Protocol Assessment, with topline results anticipated in 2025 and potential regulatory submissions in 2026 if outcomes are favorable. In May 2026, Quince announced the acquisition of OrphAI Therapeutics, extending its pipeline into rare pulmonary diseases.

Get verified Quince Therapeutics emails free

Company overview Employee directory